A detailed history of Black Rock Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 6,026,131 shares of VKTX stock, worth $255 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,026,131
Previous 8,274,174 27.17%
Holding current value
$255 Million
Previous $678 Million 52.92%
% of portfolio
0.01%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$47.39 - $80.2 $107 Million - $180 Million
-2,248,043 Reduced 27.17%
6,026,131 $319 Million
Q1 2024

May 10, 2024

BUY
$17.4 - $94.5 $11.6 Million - $63.2 Million
668,307 Added 8.79%
8,274,174 $678 Million
Q4 2023

Feb 13, 2024

BUY
$9.24 - $19.64 $4.39 Million - $9.33 Million
474,950 Added 6.66%
7,605,867 $142 Million
Q3 2023

Nov 13, 2023

BUY
$10.92 - $16.0 $2.58 Million - $3.78 Million
235,994 Added 3.42%
7,130,917 $78.9 Million
Q2 2023

Aug 11, 2023

BUY
$14.84 - $24.79 $72 Million - $120 Million
4,854,645 Added 237.94%
6,894,923 $112 Million
Q1 2023

May 12, 2023

BUY
$8.08 - $17.33 $5.61 Million - $12 Million
694,265 Added 51.58%
2,040,278 $34 Million
Q4 2022

Feb 13, 2023

SELL
$2.72 - $9.4 $327,060 - $1.13 Million
-120,243 Reduced 8.2%
1,346,013 $12.7 Million
Q3 2022

Nov 14, 2022

BUY
$2.55 - $3.89 $99,539 - $151,846
39,035 Added 2.74%
1,466,256 $3.99 Million
Q2 2022

Aug 12, 2022

SELL
$2.11 - $3.15 $7.85 Million - $11.7 Million
-3,720,240 Reduced 72.27%
1,427,221 $4.12 Million
Q1 2022

May 12, 2022

BUY
$3.0 - $4.88 $83,913 - $136,498
27,971 Added 0.55%
5,147,461 $15.4 Million
Q4 2021

Feb 10, 2022

SELL
$4.6 - $6.72 $7,557 - $11,040
-1,643 Reduced 0.03%
5,119,490 $23.5 Million
Q3 2021

Nov 09, 2021

SELL
$5.58 - $7.04 $663,556 - $837,175
-118,917 Reduced 2.27%
5,121,133 $32.2 Million
Q2 2021

Aug 11, 2021

BUY
$5.19 - $6.73 $27.2 Million - $35.3 Million
5,240,050 New
5,240,050 $31.4 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.